Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Cash from Financing Activities (2020 - 2025)

Historic Cash from Financing Activities for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to $168.7 million.

  • SAB Biotherapeutics' Cash from Financing Activities rose 2512321.01% to $168.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $168.6 million, marking a year-over-year increase of 15443.72%. This contributed to the annual value of -$1.2 million for FY2024, which is 10175.61% down from last year.
  • Per SAB Biotherapeutics' latest filing, its Cash from Financing Activities stood at $168.7 million for Q3 2025, which was up 2512321.01% from -$173844.0 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Cash from Financing Activities ranged from a high of $168.7 million in Q3 2025 and a low of -$6.3 million during Q1 2022
  • In the last 5 years, SAB Biotherapeutics' Cash from Financing Activities had a median value of -$173844.0 in 2025 and averaged $14.3 million.
  • As far as peak fluctuations go, SAB Biotherapeutics' Cash from Financing Activities surged by 3788366.89% in 2021, and later plummeted by 1379446.02% in 2022.
  • SAB Biotherapeutics' Cash from Financing Activities (Quarter) stood at $36.0 million in 2021, then tumbled by 76.72% to $8.4 million in 2022, then skyrocketed by 706.4% to $67.6 million in 2023, then crashed by 99.68% to $216961.0 in 2024, then surged by 77650.82% to $168.7 million in 2025.
  • Its Cash from Financing Activities was $168.7 million in Q3 2025, compared to -$173844.0 in Q2 2025 and -$173985.0 in Q1 2025.